ERBB2 and cancer: Trastuzumab binds to domain IV of HER2 by electrostatic and hydrophobic interactions, promoting receptor internalization, preventing dimerization and activating the antibody-dependent cellular cytotoxicity (ADCC) mechanism to kill HER2-overexpressing cancer cells [166,169].